This guideline covers care and treatment for people with, or at risk of, chronic kidney disease
(CKD). It aims to prevent or delay the progression, and reduce the risk of complications and
cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with
CKD.
NICE has produce...
The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources....
Lok, Charmaine E;
Huber, Thomas S;
Lee, Timmy;
Shenoy, Surendra;
Yevzlin, Alexander S;
Abreo, Kenneth;
Allon, Michael;
Asif, Arif;
Astor, Brad C;
Glickman, Marc H;
Graham, Janet;
Moist, Louise M;
Rajan, Dheeraj K;
Roberts, Cynthia;
Vachharajani, Tushar J;
Valentini, Rudolph P.
The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidencebased guidelines for hemodialysis vascular access since 1996. Since the last update in 2006, there has been a
great accumulation of new evidence and sophistication in the guidelines process. The 201...
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5....
The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidence-based guidelines for all stages of chronic kidney disease (CKD) and related complications since 1997. The 2015 update of the KDOQI Clinical Practice Guideline for Hemodialysis Adequacy is intended to...
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. METHODS: This guideline is based on a systematic evidence review eval...
Insuficiencia Renal Crónica/diagnóstico,
Insuficiencia Renal Crónica/tratamiento farmacológico,
Progresión de la Enfermedad,
Triaje,
Antagonistas de Receptores de Angiotensina/uso terapéutico,
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico,
Antihipertensivos/uso terapéutico,
Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico,
Hipolipemiantes/uso terapéutico,
Gemfibrozilo/uso terapéutico,
Enfermedades Asintomáticas,
Quimioterapia Combinada,
Enfoque GRADE
